Fauci, top infectious disease expert, to retire in December WASHINGTON (AP) — Dr. Anthony Fauci, the nation's top infectious disease expert who became a household name — and the subject of partisan attacks — during the COVID-19 pandemic, announced Monday he will depart the federal government in December after more than five decades of service. AP NEWS

...

Overlapping emergencies strain the nation's public health workforce and threaten critical vaccination campaigns After almost three years of contending with vaccine hesitancy, politics and a global pandemic, the nation's public health workers are frayed and leaving their posts. Now, these depleted agencies are being asked to tackle new threats like monkeypox without additional funding to handle them. Brenda Goodman, CNN Health CNN

...

New Ebola case confirmed in eastern Congo, linked to previous outbreak A new case of Ebola virus has been confirmed in the city of Beni in eastern Democratic Republic of Congo, the country's National Institute for Biomedical Research (INRB) said on Monday. Reuters Reuters

Also see:

Are you among the 1 in 5 Americans with long COVID? Here’s what you need to know about how brain-foggy—and potentially dangerous—it is Experts are developing a better understanding of long COVID, including what it does to your energy levels, cognition, and even if it can be deadly. Fortune

...

It’s hard to attribute a symptom to a condition like long COVID when that condition has yet to be clearly defined, experts say. ...

"Long COVID" response ramps up, with plans to test new treatments The research is one of several efforts by the Biden administration to address long-term symptoms that linger for some patients. YahooNews

...

The National Institutes of Health is now hoping to launch its first big clinical trials of potential treatments for patients experiencing long-term symptoms from COVID-19 as early as October, according to a top federal official overseeing the plans.

...

Omicron-specific Covid booster shots are just weeks away. Here’s who will—and won’t—be eligible

Newly updated Covid booster shots designed to target omicron’s BA.5 subvariant should be available within in the next three weeks. That begs an important question: Who’s going to be eligible to get them?

The short answer: Anyone ages 12 and up who has completed a primary vaccination series, a Centers for Disease Control and Prevention spokesperson tells CNBC Make It. It’s unlikely to matter whether you’ve received any other booster doses or not before, the spokesperson says — but if you’re unvaccinated, you won’t eligible for the updated formula until you complete a primary series with the existing Covid vaccines.

The longer answer is somewhat more complex, because it depends on which booster shots get approved and when. ...

Researchers Are Working on a New Rapid COVID-19 Immunity Test Glucose meters, which are widely available, could help test how much immunity people have to COVID-19 Time

...

In a paper published in June in the Journal of the American Chemical Society, the research team described how they developed a way to attach SARS-CoV-2 antibodies to sugar and then have the glucose reader measure those sugar levels, which reflect the antibody levels.

...

Moderna to supply 12 million doses of Omicron-targeted COVID shot to Canada Moderna Inc will supply 12 million doses of its COVID-19 shot adapted to target the Omicron variant of the coronavirus to Canada, the company said on Monday. Reuters Reuters

...

Factbox: Latest on the worldwide spread of the coronavirus Japanese Prime Minister Fumio Kishida has tested positive for COVID-19, forcing him to cancel a planned trip to Tunisia to attend a key conference on African development, a person close to him said on Sunday. Reuters Reuters

...

Which COVID boosters to take and when: a guide for the perplexed Nature - A diverse menu of vaccine options leaves people searching for the best route to protection. Ledford, Heidi nature

... the range of options, which will be available at different times, has left people wondering which vaccines to take, and when. “These are hard questions, and there are no real right answers,” says Kathryn Edwards, a paediatrician and director of the Vanderbilt Vaccine Research Program at Vanderbilt University Medical Center in Nashville, Tennessee.

Nature asked specialists what evidence is on hand to help make the decision.  ...

FDA asks Pfizer to test second Paxlovid course in patients with COVID rebound The U.S. Food and Drug Administration (FDA) has ordered Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday. Reuters Reuters

...

Serious adverse events rare after COVID-19 boosters in young kids A related study in South Korea shows waning vaccine effectiveness in teens. CIDRAP

Data collected from two vaccine safety surveillance programs in the first 10 weeks of administration of third doses of the Pfizer/BioNTech COVID-19 to US children aged 5 to 11 years show that serious adverse events were rare.

Over half of people infected with the omicron variant didn't know it, a study finds These undiagnosed infections could be a major factor in the rapid transmission of the omicron variant, the researchers said. NPR.org

The majority of people likely infected with the omicron variant that causes COVID-19 were not aware they contracted the virus, which likely played a role in the rapid spread of omicron, according to a study published this week.

...

...

What the Inflation Reduction Act means for health care coverage About two-thirds of Americans now support such a guarantee, and the time has come to make it happen. cayala The Hill

 ...